BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 23072227)

  • 1. Treating Crohn's disease: at "deep" remission and exploring beyond.
    Corte C; Selby WS
    Med J Aust; 2012 Oct; 197(8):430-1. PubMed ID: 23072227
    [No Abstract]   [Full Text] [Related]  

  • 2. Listeria monocytogenes infection in Crohn's disease treated with adalimumab.
    Willson KJ; Jacob A; Shetti MP; Bhatia R; Yee K; Osler W
    Med J Aust; 2012 Oct; 197(8):466-7. PubMed ID: 23072245
    [No Abstract]   [Full Text] [Related]  

  • 3. Sarcoidosis complicating treatment with adalimumab for Crohn's disease.
    McDonnell MJ; Rutherford RM; O'Regan A
    J Crohns Colitis; 2014 Sep; 8(9):1140-1. PubMed ID: 24631310
    [No Abstract]   [Full Text] [Related]  

  • 4. Adalimumab-induced psoriasis in a patient with Crohn's disease.
    Korkmaz U; Duman AE; Dindar G; Yilmaz H; Dursun IH; Celebi A; Senturk O; Hulagu S
    Indian J Gastroenterol; 2013 Mar; 32(2):135-6. PubMed ID: 23151897
    [No Abstract]   [Full Text] [Related]  

  • 5. Acute coronary syndrome in a Crohn's disease patient treated with adalimumab.
    Petitpain N; Bornert-Keller N; Peyrin-Biroulet L
    J Crohns Colitis; 2013 Oct; 7(9):e396. PubMed ID: 23523265
    [No Abstract]   [Full Text] [Related]  

  • 6. Guillain-Barrè syndrome after treatment with human anti-tumor necrosis factorα (adalimumab) in a Crohn's disease patient: case report and literature review.
    Cesarini M; Angelucci E; Foglietta T; Vernia P
    J Crohns Colitis; 2011 Dec; 5(6):619-22. PubMed ID: 22115384
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A case of adalimumab-induced pneumonitis in a 45-year-old man with Crohn's disease.
    Reid JD; Bressler B; English J
    Can Respir J; 2011; 18(5):262-4. PubMed ID: 21969926
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Level of adalimumab and its antibody titers define the effectiveness of the biological (anticytokine) therapy in Crohn's disease].
    Lazebnik LB; Sagynbaeva VÉ
    Eksp Klin Gastroenterol; 2013; (7):18-22. PubMed ID: 24772870
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumor necrosis factor-alpha antibody for maintenance of remission in Crohn's disease.
    Behm BW; Bickston SJ
    Cochrane Database Syst Rev; 2008 Jan; (1):CD006893. PubMed ID: 18254120
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Infliximab-induced acute hepatitis during Crohn's disease therapy: absence of cross-toxicity with adalimumab.
    Haennig A; Bonnet D; Thebault S; Alric L
    Gastroenterol Clin Biol; 2010 Sep; 34(8-9):e7-8. PubMed ID: 20189334
    [No Abstract]   [Full Text] [Related]  

  • 11. Adalimumab-induced interstitial pneumonia in a patient with Crohn's disease.
    Casanova MJ; Chaparro M; Valenzuela C; Cisneros C; Gisbert JP
    World J Gastroenterol; 2015 Feb; 21(7):2260-2. PubMed ID: 25717268
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Severe adalimumab-induced thrombocytopenia in a patient with Crohn's disease.
    Casanova MJ; Chaparro M; Martínez S; Vicuña I; Gisbert JP
    J Crohns Colitis; 2012 Dec; 6(10):1034-7. PubMed ID: 22534313
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Severe cardiomyopathy following treatment with the tumour necrosis factor-alpha inhibitor adalimumab for Crohn's disease.
    Emmert MY; Salzberg SP; Emmert LS; Behjati S; Plass A; Felix C; Falk V; Gruenenfelder J
    Eur J Heart Fail; 2009 Nov; 11(11):1106-9. PubMed ID: 19875411
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multiple and fulminant cutaneous squamous cell carcinomas in a Crohn's disease patient treated with immunosuppressants and adalimumab.
    Nancey S; Boschetti G; Cotte E; Cathey-Javouhay A; Laidet M; Chichery A; Francois Y; Glehen O; Flourié B
    Inflamm Bowel Dis; 2011 Apr; 17(4):1060-1. PubMed ID: 21391289
    [No Abstract]   [Full Text] [Related]  

  • 15. First case report of adalimumab-induced psoriasis in Crohn's disease.
    Harris MD; Richards R
    Am J Gastroenterol; 2009 Mar; 104(3):792-3. PubMed ID: 19262532
    [No Abstract]   [Full Text] [Related]  

  • 16. [Efficacy and safety of Adalimumab in Crohn's disease].
    Serghini M; Haddad W; Jeddi H; Karoui S; Ben Mustapha N; Kallel L; Fekih M; Matri S; Boubaker J; Filali A
    Tunis Med; 2012 Feb; 90(2):101-7. PubMed ID: 22407620
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adalimumab-induced lupus erythematosus in Crohn's disease patients previously treated with infliximab.
    Mañosa M; Domènech E; Marín L; Olivé A; Zabana Y; Cabré E; Gassull MA
    Gut; 2008 Apr; 57(4):559; author reply 559-60. PubMed ID: 18334664
    [No Abstract]   [Full Text] [Related]  

  • 18. Ventricular tachyarrhythmia after adalimumab therapy in a patient with Crohn's disease.
    Eder P; Lykowska-Szuber L; Krela-Kazmierczak I; Stawczyk-Eder K; Linke K
    Acta Gastroenterol Belg; 2013 Mar; 76(1):74-5. PubMed ID: 23650791
    [No Abstract]   [Full Text] [Related]  

  • 19. Commentary: infliximab or adalimumab in Crohn's disease?
    Sprakes MB; Hamlin PJ
    Aliment Pharmacol Ther; 2012 Aug; 36(4):398. PubMed ID: 22803644
    [No Abstract]   [Full Text] [Related]  

  • 20. Letter: infliximab and adalimumab in the management of Crohn's disease--are they really comparable?
    Lopez-Sanroman A; Gisbert JP
    Aliment Pharmacol Ther; 2012 Sep; 36(5):498-9. PubMed ID: 22860615
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.